
    
      This open label, single-arm and multicenter phase II study is designed to evaluate Objective
      Response Rate (ORR) of anti-EGFR monoclonal antibody（SCT200）in Recurrent and/or Metastatic
      Head and Neck Squamous Cell Carcinoma after failure of platinum-based therapy.
    
  